Gift from Berger boosts RSNA scholarship fund
Dr. Paul E. Berger, founder and CEO of NightHawk Radiology Services, has donated $1.5 million to the RSNA's Research and Education Foundation to endow the Derek Harwood-Nash Scholar Grant. The fellowship program will help young academic radiologists from outside the U.S. travel to North America for advanced research training.
Dr. Paul E. Berger, founder and CEO of NightHawk Radiology Services, has donated $1.5 million to the RSNA's Research and Education Foundation to endow the Derek Harwood-Nash Scholar Grant. The fellowship program will help young academic radiologists from outside the U.S. travel to North America for advanced research training.
The endowment is a personal tribute to the late Harwood-Nash, who was born in the former British colony of Southern Rhodesia in 1936 and trained in South Africa, England, and Canada before conducting pioneering work that led to the subspecialty of pediatric neuroradiology. He died in Toronto in 1997
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
